← All trials
NCT07174297
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 30, 2025
- Primary completion
- Dec 30, 2026
- Completion date
- Apr 30, 2027
- First posted
- Sep 15, 2025
- Last posted
- Sep 23, 2025
- Enrollment
- 152
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Getz PharmaLead sponsor
- Rawalpindi Medical College, PakistanCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.